Ø

Approved for use through 10/31/2002 OMB 0651-003, Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons collection of information unless it displays a valid OMB control numb UTILITY Attorney Docket No. Vladimir Gartstein PATENT APPLICATION First Inventor The Procter & Gamble Company TRANSMITTAL Assignee (Only for new nonprovisional applications Method and Apparatus for the In-Vivo Treatment under 37 CFR 1.53(b)) Title of Pathogens EF187735938US Express Mail Label No. APPLICATION ELEMENTS **Box Patent Application** ADDRESS TO: **Assistant Commissioner for Patents** See MPEP Chapter 600 concerning utility patent application contents. Washington, D.C. 20231 1. [x] Fee Transmittal Form (e.g., PTO/SB/17) 6. [] CD-ROM or CD-R in duplicate, large table (Submit an original, and a duplicate for fee processing) or Computer Program (Appendix) 2. [x] Specification Total Pages [28] 7. Nucleotide and/or Amino Acid Sequence Submission (preferred arrangement set forth below) (if applicable, all necessary) - Descriptive Title of the Invention a. [] Computer Readable Form (CRF) b. Specification Sequence Listing on: - Cross References to Related Applications i. [] CD-ROM or CD-R (2 copies); or - Statement Regarding Fed sponsored R&D ii. [] Paper Reference to sequence listing, a table, or a computer program listing appendix - Background of the Invention C. Statement verifying identity of above copies - Brief Summary of the Invention **ACCOMPANYING APPLICATION PARTS** Brief Description of the Drawings (if filed) 8. [] Assignment Papers (cover sheet & document(s)) - Detailed Description 9. [] 37 CFR 3.73(b) Statement Power of Attorney Claim(s) (when there is an assignee) - Abstract of the Disclosure 3. [x] Drawing(s) (35 USC §113) Total Sheets [4] 10. [] English Translation Document (if applicable) 11. [] Information Disclosure 4. Oath or Declaration Total pages [2] [] Copies of IDS Newly executed (original or copy) Statement (IDS)/PTO-1449 Citations 12. [] Preliminary Amendment [] Copy from a prior application (37 CFR §1.63(d)) (for continuation/divisional with Box 17 complete DELETION OF INVENTORS 13. [x] Return Receipt Postcard (MPEP 503) Signed statement attached deleting inventor(s) (Should be specifically itemized) named in the prior application, 14. [] Certified Copy of Priority Document(s) see 37 CFR §§1.63(d)(2) and 1,33(b). (if foreign priority is claimed) 15. [] Nonpublication Request under 35 U.S.C. 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.

5. [] Application Data Sheet. See 37 CFR §1.76

	[16. [] Other:		
17. If a CONTINUING APPLICATION, check appropriate to	oox and supply the requisite information below and in a preliminary		
amendment, or in an Application Data Sheet under 37 CFR §1.76:			
[] Continuation [] Divisional [] Continuation-in-part (CIP)	of prior application No. /		
Prior application information: Examiner:	Group/Art Unit:		
For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.			
19. CORRESPONDE	NCE ADDRESS		
[X] Customer Number (Insert Customer No. here)	12		
	2		

Name (Print/Type)	Ian S. Robinson	Registration No. (Attorney/Agent)	43,348
Signature	Ian Robinsion	Date	Feb. 19, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE	TRANSMITTAL
	for FY 2002

£

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$)824.00

Complete if Known		
Application Number		
Confirmation Number		
Filing Date	February 19, 2002	
First Named Inventor	Vladimir Gartstein	
Examiner Name		
Group/Art Unit		
Attorney Docket No.	8431	

METHOD OF PAYMENT (check one) FEE CALCULATION (continued)			
1. [X] The Commissioner is hereby authorized to charge indicated	3. ADDITIONAL FEES		
fees and credit any over payments to:	Code (\$) Fee Description Fee Paid		
Deposit Account Number 16-2480	105 130 Surcharge-late filing fee or oath		
Deposit Account Name The Procter & Gamble Company	127 50 Surcharge-late provisional filing fee or cover sheet []		
X Charge Any Additional Fee Required Under status. 37 C.F.R. §§1.16 and 1.17	139 130 Non-English specification []		
	147 2,520 For filing a request for ex parte reexamination []		
	112 920* Requesting publication of SIR prior to		
	Examiner's action []		
FEE CALCULATION	113 1,840* Requesting publication of SIR after		
FEE CALCULATION	Examiner's action []		
1. BASIC FILING FEE - Large Entity	115 110 Extension for reply within 1 st month		
**	116 400 Extension for reply within 2 nd month []		
	1		
Code (\$) Fee Description Fee Paid 101 740 Utility filing fee 740.00	117 920 Extension for reply within 3 rd month		
L. d. Company and	118 1,440 Extension for reply within 4 th month		
. sal	128 1,960 Extension for reply within 5 th month		
108 740 Reissue filing fee [] 114 160 Provisional filing fee	119 320 Notice of Appeal [] 120 320 Filing a brief in support of an appeal []		
114 160 Provisional filing fee []	[
SUBTOTAL (1) (\$)740.00			
(\$)740.00	138 1,510 Petition to institute a public use proceeding [] 140 110 Petition to revive - unavoidable		
2 EVEDA CLAIM EDEC EOD HEEL EVAND DERCOTE			
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE - Large Entity	141 1,280 Petition to revive - unintentional []		
Extra Fee from Fee	142 1,280 Utility issue fee (or reissue) [] 143 460 Design issue fee		
Claims Below Paid	143 460 Design issue fee [] 122 130 Petitions to the Commissioner []		
Total Claims $20 - 20^{**} = 0 \times [] = []$			
Total claims 20 - 20 - 2 0 X II - II	123 50 Petitions related to provisional applications [] (37 C.F.R. 1.17(q))		
Independent Claims $4 - 3^{**} = 1 \times 84.00 = 84.00$	126 180 Submission of Information Disclosure Statement []		
Multiple Dependent [] = []	146 740 Filing a submission after final rejection		
** or number previously paid, if greater; For Reissues, see below	(37 CFR § 1.129(a)) []		
	149 740 For each additional invention to be		
Code (\$) <u>Fee Description</u>	examined (37 CFR §1.129(b)		
103 18 Claims in excess of 20	179 740 Request for Continued Examination (RCE) []		
102 84 Independent claims in excess of 3	169 900 Request for expedited examination [] of a design application		
104 280 Multiple dependent claim, if not paid	091 1280 Acceptance of unintentionally delayed claim for		
109 84 **Reissue independent claims over original patent	priority under 35 U.S.C. 119, 120, 121, or 365 (a) or (c)		
110 18 **Reissue claims in excess of 20 & over original patent			
	Other fee (specify)		
	Other fee (specify)		
SUBTOTAL (2) (\$)84.00	* Reduced by Basic Filing Fee Paid SUBTOTAL(3) (\$) []		

SUBMITTED BY					Comple	te (if applicable)
Name (Print/Type)	Ian S. Robinson	1 -	Registration No. (Attorney/Agent)	43,348	Telephone	(513) 626-3356
Signature	Ian ho	nunco	7		Date	Feb. 19, 2002

WARNING: Information on this form may become public. Credit Card information should not be included on this form. Provide credit card information and authorization on PTO-2033.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information of PTO-2031.

THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.